logo
welcome
CNBC

CNBC

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

CNBC
Summary
Nutrition label

79% Informative

The FDA still has to make a final decision on whether to bar those unapproved versions of semaglutide.

The active ingredient in Wegovy and Ozempic has been in intermittent shortages over the past two years .

Novo Nordisk has filed 50 lawsuits against several clinics, compounding pharmacies and other manufacturers over the last year .